BOSTON -- Sonus Pharmaceuticals (SNUS - Cramer’s Take - Stockpickr - Rating) is nearing a make-or-break milestone for its experimental cancer drug.The small Seattle-based biotech firm is preparing to release top-line results from a pivotal phase III study of Tocosol paclitaxel, a reformulation of the broadly used chemotherapy drug paclitaxel, which is known by its brand name Taxol.
